19 April 2013
BIO International Convention (BIO-2013). Chicago, USA.
Session «Spotlight on the BRICs: Russia»
Monday, Apr 22, 2013
Biotechnology innovation is an engine of economic growth. Many countries have thus made the development of a biotechnology sector an economic priority and have allocated significant resources into its development. While the established markets remain a vital source of new discoveries and business opportunities, the emerging markets are becoming increasingly attractive as governments implement national strategies for biotechnology growth and development. This program will highlight and explore the development strategies of the four BRIC nations. The panels in this program are designed to identify and discuss specific initiatives within each country that are driving the pace of biotechnology innovation. Each nation will have a dedicated half-day program.
8:30 a.m. - 9:15 a.m. - Welcome & Keynote Presentation
Rogerio Ribeiro, Vice President, Emerging Markets, GSK
Nikolay Fedorovich Gerasimenko, First Deputy Chairman, Committee on Health, State Duma of the Russian Federation Acad.
Valeriy Alexandrovich Chereshnev, Chairman, Committee on Science & Innovations, State Duma of the Russian Federation
9:15 a.m. - 10:30 a.m. - Pharma 2020: Russia's Transformation from Emerging to One of the Fastest Growing Pharmaceutical Markets
Government support and initiatives are critical to creating an ideal environment for a country to grow as a biopharmaceutical hub. Russia is striving to reach the goals set up by the Russian government in its Pharma2020 program. This interactive panel will discuss the first results of Pharma2020. Speakers will cover the following topics: changes in the Russian regulatory system; first results of the federal program's implementation; main factors contributing to the high growth of the Russian pharmaceutical market; how the phenomenon of "reverse innovation" can help maximize pharma opportunities in high growth markets; and WTO's impact on the Russian pharmaceutical market. Major deals concluded between Big Pharma and Russian companies will be highlighted. Session attendees will learn more about existing opportunities available for the international partnerships on the Russian market. Executives from pharmaceutical companies operating in Russia will be present to provide additional ‘expert’ commentary.
Moderator: Wendy Diller, Chief, Biopharma Business Bureau, Elsevier
Sergey Tsyb, Head of the Department, Ministry of Industry and Trade, Russia
Andrey Ivashchenko, Chairman of the Board, ChemRar High Tech Center, Russia
Alexey Repik, Chairman of the Board at R-Pharm, Russia
Alberto Colzi, Vice-president Operations, AbbVie, USA
Oleg Demidov, Director of the Department, Vnesheconombank
Rogerio Ribeiro, VP of Emerging Markets, GSK, United Kingdom
Evgeny Kuznetsov, Executive Board Member, Russian Venture Company
Prof. Konstantin Skryabin, Director of the Centre "Bioengineering" Russian Academy of Sciences
Petr Radionov, CEO of Geropharm, Russia
10:45 a.m.-12:00 p.m. - The Role of Biopharm Clusters in the Modernization and Technological Development of the Russian Economy
The panel will examine the role of key elements of the Russian biopharm and med- clusters creation and plans for clusters further development in Russia. The Russian government actively provides state financial support, institutional grants and portfolio investments in venture funds. Number of Government programs, including the Ministry of Economic Development initiatives, are targeted to provide clusters participants with the access to the most advanced scientific and educational resources, invest in the clusters infrastructure and to create more favorable conditions for the investments. Private capital and industry work closely to create the instruments of the venture financing, build product focused R&D and manufacturing with regional and global market access. Academia, educational and applied research institutions provide sources of IP and human capital, serve as a " baseboard” for public-private partnership, coordinate public instruments with private interests and money. The advantages and the most successful examples of international pharmaceutical companies working in the innovative and most advanced clusters (BiopharmCluster “Northern”, St Petersburg, Yaroslavl), support provided by the Russian Development institutions (Skolkovo Foundation, Vnesheconombank, Rusnano) will be discussed by key participants during this interactive session. Speakers and experts will be represented by federal and regional government authorities, state development institutions, executives from pharm-, bio- and medical clusters, representatives of the international pharmaceutical companies and research scientists.
Moderator: Marina Bozilenko, Head of Biotechnology & Pharma, William Blair & Company, LLC
Oleg Fomichev, Deputy Minister of Economic Development, Russia
Igor Agamirzyan, CEO of Russian Venture Company
Nikolay Savchuk, Director of the Center for Strategic Development, Moscow Intsitute of Physics and Technology
Ivan Bortnik, Executive Director of the Association of Innovative Regions of Russia
Anna Protopapas, Executive VP Global Business Development, Takeda, USA
Oleg Korzinov, Executive Director of Biopharm?luster "Northern", Russia
Zakhar Golant, ?hairman of "Medical and pharmaceutical projects. XXI century", NCP, Russia
Marek Dziki, Executive Director of Biomed cluster Skolkovo, Russia
Fabrice Egros, Sr. Executive director, Novamedica, Russia
Dmitry Kulish, Executive Vice President, Nanolek, Russia
Sergey Yastrebov, Governor of Yaroslavl region, Russia
18 August 2017
18 August 2017
17 August 2017
17 August 2017